Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42456135
Explore the impact of lenalidomide maintenance therapy duration on survival and adverse events in multiple myeloma patients.
Lenalidomide maintenance therapy in multiple myeloma showed comparable overall survival between regimens in patients not undergoing up-front stem-cell transplantation. Indefinite therapy had more adverse events.
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42161729
Explore ciltacabtagene autoleucel in RRMM, linked to CNP and IEC-parkinsonism, with incidence varying by treatment lines and high CAR-T expansion increasing neurologic risk.
Ciltacabtagene autoleucel shows potential in RRMM, with 6.3% experiencing CNP. IEC-parkinsonism varies with treatment lines (1% vs. 6%). High CAR-T expansion increases neurologic risk.
Multiple myeloma: A tale of deregulated transcription factors. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42388417
Explore how deregulated transcription factors contribute to multiple myeloma and the emerging therapeutic strategies, including siRNA-loaded lipid nanoparticles and PROTACs, targeting these crucial gene expression regulators.
Transcription factors like IRF4 and PRDM1 are crucial in multiple myeloma pathogenesis. Emerging therapies, such as siRNA-loaded lipid nanoparticles and PROTACs, target these factors.
Efficacy of Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma With Extramedullary Disease: A Systematic Review and Meta-Analysis. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42359424
Bispecific antibodies show varied efficacy in RRMM with EMD; teclistamab 58.3%, elranatamab 38.5%, linvoseltamab 52.6%, talquetamab 44.6%. Pooled ORR: 45.2%.
Bispecific antibodies yield responses in 45.2% of RRMM patients with EMD; ORRs: teclistamab 58.3%, elranatamab 38.5%, linvoseltamab 52.6%, talquetamab 44.6%. Caution due to variability.
Monoclonal Gammopathy as a Potential Cause of Pure Red Cell Aplasia: A Case Report and Literature Review. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42317887
Explore a case of PRCA linked to monoclonal gammopathy, where plasma cell-targeted therapy rapidly normalized erythropoiesis, hinting at a potential antibody-mediated mechanism.
Plasma cell-directed therapy rapidly normalized erythropoiesis and cleared paraproteins in PRCA linked to monoclonal gammopathy, suggesting an antibody-mediated mechanism.